Literature DB >> 30071173

Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features.

Bogna Grygiel-Górniak1, Nattakarn Limphaibool1, Katarzyna Perkowska1, Mariusz Puszczewicz1.   

Abstract

BACKGROUND: Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.
METHOD: An extensive electronic literature search was done using multiple databases (e.g. PubMed) from January 2007 to August 2017 to gather information on the etiopathogenesis, clinical presentation, and current treatment management plan of GPA. The language used was English. Search items included 'Granulomatosis with Polyangiitis symptoms,' 'Wegener's Granulomatosis,' and 'Treatment of Granulomatosis with Polyangiitis' for the databases. Inclusion criteria consisted of published articles in the English language which reported on the clinical manifestations of GPA, as well as on the treatment of the disease. Exclusion criteria included articles that: (1) did not specifically report on GPA vasculitis but also focused on discussion of other vasculitis such as MPA or Churg-Strauss; (2) reported on treatment/symptoms of GPA prior to 2007. RESULT: This review provides an overview of work undertaken in key areas of GPA research, including its complex multifactorial etiology, clinical manifestations, treatment strategies, and treatment-related adverse effects.
CONCLUSION: Major advances in the understanding and treatment of GPA over recent decades have contributed to the notable decline in morbidity and mortality of patients. The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.

Entities:  

Keywords:  Granulomatosis with polyangiitis; diagnosis; etiopathogenesis; treatment

Mesh:

Substances:

Year:  2018        PMID: 30071173     DOI: 10.1080/00325481.2018.1503920

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  7 in total

1.  Tension Pneumothorax as Initial Manifestation of Granulomatosis with Polyangiitis (GPA).

Authors:  Rúben Reis; Anneke Joosten; Francelino Ferreira; Magda Silva; Catarina Parente; Inês Maia
Journal:  Eur J Case Rep Intern Med       Date:  2021-02-11

2.  Factors Affecting Dilation Interval in Patients With Granulomatosis With Polyangiitis-Associated Subglottic and Glottic Stenosis.

Authors:  Lena W Chen; Ioan Lina; Kevin Motz; Alexandra J Berges; Rafael Ospino; Philip Seo; Alexander T Hillel
Journal:  Otolaryngol Head Neck Surg       Date:  2021-04-13       Impact factor: 3.497

3.  Atypical painless vision loss in a patient with granulomatosis with polyangiitis.

Authors:  Patricia C Nelson; Vamsi Kunam; Claudia Prospero Ponce
Journal:  GMS Ophthalmol Cases       Date:  2020-12-15

4.  A destructive centrofacial granuloma: Case report.

Authors:  Zineb Tazi Saoud; Fatima Zahra Elfatoiki; Soumiya Chiheb
Journal:  Ann Med Surg (Lond)       Date:  2022-02-08

5.  Time-dependent risk of mortality and end-stage kidney disease among patients with granulomatosis with polyangiitis.

Authors:  Chun-Yu Lin; Hung-An Chen; Tsang-Wei Chang; Tsai-Ching Hsu; Chung-Yuan Hsu; Yu-Jih Su
Journal:  Front Med (Lausanne)       Date:  2022-08-10

6.  Amnesia in a Patient with Rheumatoid Arthritis: A Case of Granulomatosis with Polyangiitis.

Authors:  Pablo Weilg; Giancarlo Diaz-Zamora; Larry Young
Journal:  Case Rep Rheumatol       Date:  2020-10-29

7.  Granulomatosis With Polyangiitis Associated With Hemophagocytic Lymphohistiocytosis: A Rarely Reported Complication.

Authors:  Turab Mohammed; Steffi Thomas; Melissa Sepúlveda-Ramos; Padmanabhan Premkumar; Krzysztof Glomski; Mark Dailey; Christine McCrary; William N Rezuke
Journal:  J Clin Rheumatol       Date:  2021-12-01       Impact factor: 3.902

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.